重度哮喘的创新疗法
Innovative Therapies for Severe Asthma.
作者信息
Christensen Maj Anna, Ott Michael
机构信息
and are physicians at Eglin Air Force Hospital in Valparasio, Florida.
出版信息
Fed Pract. 2017 Dec;34(12):25-31.
Abstract
Severe asthma therapies have progressed to include many options that have improved the quality of life for patients.
摘要
重症哮喘治疗方法不断进步，出现了多种选择，改善了患者的生活质量。
相似文献
1
Innovative Therapies for Severe Asthma.重度哮喘的创新疗法
Fed Pract. 2017 Dec;34(12):25-31.
2
Needs for Systems Approaches to Better Treat Individuals With Severe Asthma: Predicting Phenotypes and Responses to Treatments.采用系统方法更好地治疗重度哮喘患者的需求：预测表型和治疗反应
Front Med (Lausanne). 2020 Mar 31;7:98. doi: 10.3389/fmed.2020.00098. eCollection 2020.
3
Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?重度难治性哮喘的创新治疗方法：如何为合适的患者选择正确的治疗方案？
J Asthma Allergy. 2017 Aug 30;10:237-247. doi: 10.2147/JAA.S144100. eCollection 2017.
4
Severe Asthma in Primary Care: Identification and Management.基层医疗中的重度哮喘：识别与管理。
Am J Med. 2018 May;131(5):484-491. doi: 10.1016/j.amjmed.2017.12.034. Epub 2018 Mar 30.
5
Treatment of severe, uncontrolled eosinophilic asthma: Where we are heading.重度、未控制的嗜酸性粒细胞性哮喘的治疗：我们的发展方向。
J Asthma. 2019 May;56(5):459-472. doi: 10.1080/02770903.2018.1471708. Epub 2018 Oct 16.
6
Primary care of asthma: new options for severe eosinophilic asthma.哮喘的初级保健：严重嗜酸性粒细胞性哮喘的新选择。
Curr Med Res Opin. 2019 Jul;35(7):1309-1318. doi: 10.1080/03007995.2019.1595966. Epub 2019 Apr 29.
7
Clinical Issues in Severe Asthma: Consensus and Controversies on the Road to Precision Medicine.《重症哮喘的临床问题：迈向精准医学的共识与争议》。
Chest. 2018 Oct;154(4):982-983. doi: 10.1016/j.chest.2018.08.1022.
8
Severe asthma: Current management, targeted therapies and future directions-A roundtable report.重度哮喘：当前管理、靶向治疗及未来方向——一份圆桌会议报告
Respirology. 2017 Jan;22(1):53-60. doi: 10.1111/resp.12957. Epub 2016 Nov 30.
9
A review of the use of adjunctive therapies in severe acute asthma exacerbation in critically ill children.辅助治疗在危重症儿童中重度哮喘急性发作中的应用综述。
Expert Rev Respir Med. 2014 Aug;8(4):423-41. doi: 10.1586/17476348.2014.915752. Epub 2014 Jul 4.
10
[Innovative therapies for severe asthma: the role of monoclonal antibodies].[重度哮喘的创新疗法：单克隆抗体的作用]
Rev Prat. 2011 Mar;61(3):362-3.
引用本文的文献
1
Precision Medicine for Paediatric Severe Asthma: Current Status and Future Direction.儿童重症哮喘的精准医学：现状与未来方向
J Asthma Allergy. 2021 May 20;14:525-538. doi: 10.2147/JAA.S265657. eCollection 2021.
2
Living well with severe asthma.重度哮喘患者的良好生活状态。
Breathe (Sheff). 2019 Jun;15(2):e40-e49. doi: 10.1183/20734735.0165-2019.
本文引用的文献
1
Novel Biologicals for the Treatment of Allergic Diseases and Asthma.用于治疗过敏性疾病和哮喘的新型生物制剂。
Curr Allergy Asthma Rep. 2016 Oct;16(10):70. doi: 10.1007/s11882-016-0650-5.
2
Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone.布地奈德联用福莫特罗与单用布地奈德治疗严重哮喘事件的比较。
N Engl J Med. 2016 Sep 1;375(9):850-60. doi: 10.1056/NEJMoa1511190.
3
Affirmation of the adoration of the vagi and role of tiotropium in asthmatic patients.关于迷走神经崇拜及噻托溴铵在哮喘患者中的作用的肯定。
J Allergy Clin Immunol. 2016 Oct;138(4):1011-1013. doi: 10.1016/j.jaci.2016.06.024. Epub 2016 Jul 22.
4
Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.非索罗肽，一种前列腺素 D2 受体 2 拮抗剂，在持续性嗜酸性粒细胞性哮喘患者中的应用：一项单中心、随机、双盲、平行分组、安慰剂对照试验。
Lancet Respir Med. 2016 Sep;4(9):699-707. doi: 10.1016/S2213-2600(16)30179-5. Epub 2016 Aug 5.
5
Traditional Therapies for Severe Asthma.重度哮喘的传统疗法
Immunol Allergy Clin North Am. 2016 Aug;36(3):581-608. doi: 10.1016/j.iac.2016.03.013.
6
Role of Small Airways in Asthma.小气道在哮喘中的作用。
Immunol Allergy Clin North Am. 2016 Aug;36(3):473-82. doi: 10.1016/j.iac.2016.03.009.
7
The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma.口服CRTh2拮抗剂QAW039（非维普拉特）：一项针对未控制的过敏性哮喘的II期研究。
Pulm Pharmacol Ther. 2016 Aug;39:54-63. doi: 10.1016/j.pupt.2016.06.005. Epub 2016 Jun 21.
8
Dupilumab: a potential new treatment for severe asthma.度普利尤单抗：一种治疗重度哮喘的潜在新疗法。
Lancet. 2016 Jul 2;388(10039):3-4. doi: 10.1016/S0140-6736(16)30311-7. Epub 2016 Apr 27.
9
Benralizumab: a unique IL-5 inhibitor for severe asthma.贝那利珠单抗：一种用于重度哮喘的独特白细胞介素-5抑制剂。
J Asthma Allergy. 2016 Apr 4;9:71-81. doi: 10.2147/JAA.S78049. eCollection 2016.
10
Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.美泊利珠单抗治疗既往使用奥马珠单抗治疗的重度嗜酸性粒细胞性哮喘患者的疗效
Allergy. 2016 Sep;71(9):1335-44. doi: 10.1111/all.12914. Epub 2016 May 24.
Zotero 插件